RxDoctor Payments Data

Karina Salomon, APRN

Nurse Practitioner · Honolulu, HINPI 1174144075

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,474 of the $1,653 with a category attached, or 89.2%. It is spread thinly across 18 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $890, more than ten times the $38 reported in 2021.

$1,653in general payments, 2019–2025

Across 34 payments — averaging $48.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$279
  • AstraZeneca$195
  • Incyte Corporation$193
  • Pharmacosmos Therapeutics Inc.$146
  • Sanofi$135
  • Lilly USA, LLC$119
  • plus $585 from 12 others

What the payments were for

  • Food & beverage$1,47489%
  • Education$17911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,653 in reported general payments places this provider in the 80th percentile of 215 nurse practitioner providers in Hawaii.

See all nurse practitioner providers in Hawaii

Medicare billing

Part B allowed, 2024
$4,049
Medicare patients
52
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib18$282,891
Abiraterone Acetate12$81,050
Deferasirox20$34,469
EliquisApixaban16$13,197
Exemestane17$3,898
Anastrozole46$2,035
Letrozole34$621
Hydroxyurea21$484
Tamoxifen Citrate18$431
Dexamethasone25$394
Ondansetron OdtOndansetron18$358
Alendronate Sodium20$203
Prochlorperazine Maleate13$110
Prednisone28$95
Levothyroxine Sodium14$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$279$296,08834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 nurse practitioner providers in Hawaii.

Other nurse practitioner in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →